MicroRNA HSA-miR-125a-5p induces apoptosis by activating p53 in lung cancer cells

Experimental Lung Research

Volumn 37, Issue 7, 2011, Pages 387-398

  Jiang, Lili ^a   Huang, Qin ^b   Chang, Jihong ^c   Wang, Enhua ^c   Qiu, Xueshan ^c  

^a EASTERN LIAONING UNIVERSITY   (China)

^b Jintan People's Hospital   (China)

^c CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Hsa miR 125a 5p; Lung cancer; MiR 125a; P53

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; HSA MICRORNA 125A 5P; MICRORNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PAB122; PLASMID VECTOR; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BRONCHUS MUCOSA; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICRORNAS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80051827246     PISSN: 01902148     EISSN: 15210499     Source Type: Journal    
DOI: 10.3109/01902148.2010.492068     Document Type: Article

References (54)

1. Hollstein M, Sidransky D, Vogelstein B, Harris CC: P53 mutations in human cancers. Science. 1991;253:49-53.
2. Soussi T: P53alterations in human cancer: More questions than answers. Oncogene. 2007;26:2145-2156.
3. Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature. 2000;408:307-310.
4. Vousden KH, Lane DP: P53 in health and disease. Nat Rev Mol Cell Biol. 2007;8:275-283.
5. Oren M: Decision making by p53: Life, death and cancer. Cell Death Differ. 2003;10:431-442.
6. Lee RC, Feinbaum RL, Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843-854.
7. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Radmark O, Kim S, Kim VN: The nuclear RNase III Drosha initiates microRNA processing. Nature. 2003;425:415-419
8. Kong W, Zhao JJ, He L. Cheng JQ: Strategies for profiling microRNA expression. J Cell Physiol. 2009;218:22-25
9. Hutvágner G,McLachlan J, Pasquinelli AE, Bálint E, Tuschl T, Zamore PD: A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science. 2001;293:834-838.
10. Grishok A, Pasquinelli AE, Conte D, Li N, Parrish S, Ha I, Baillie DL, Fire A, Ruvkun G, Mello CC: Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control C. elegans developmental timing. Cell. 2001;106:23-34.
11. Schwarz DS, Hutvágner G, Du T, Xu Z, Aronin N, Zamore PD: Asymmetry in the assembly of the RNAi enzyme complex. Cell. 2003;115:199-208.
12. Ørom UA, Nielsen FC, Lund AH: MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell. 2008;30:460-471.
13. Brennecke J, Stark A, Russell RB, Cohen SM: Principles of microRNA-target recognition. PLoS Biol. 2005;3:e85.
14. Bartel DP: MicroRNAs genomics, biogenesis, mechanism, and function. Cell. 2004;116:281-297.
15. Ren J, Jin P,Wang E, Marincola FM, Stroncek DF:MicroRNA and gene expression patterns in the differentiation of human embryonic stem cells. J Transl Med. 2009;7:20.
16. Foshay KM, Gallicano GI: MiR-17 family miRNAs are expressed during early mammalian development and regulate stem cell differentiation. Dev Biol. 2009;326:431-443.
17. Wu H, Zhu S, Mo YY: Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res. 2009;19439-448.
18. Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY: MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesionindependent growth. Cancer Res. 2007;67:8433-8438.
19. BuenoMJ, de Castro IP,Malumbres M: Control of cell proliferation pathways by microRNAs. Cell Cycle. 2008;7:3143-3148.
20. Liu X, Nelson A, Wang X, Kanaji N, Kim M, Sato T, Nakanishi M, Li Y, Sun J, Michalski J, Patil A, Basma H, Rennard SI: MicroRNA-146a modulates human bronchial epithelial cell survival in response to the cytokine-induced apoptosis. Biochem Biophys Res Commun. 2009;380:177-182.
21. Liu X, Nelson A, Wang X, Kanaji N, Kim M, Sato T, Nakanishi M, Li Y, Sun J, Michalski J, Patil A, Basma H, Rennard SI: Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem. 2008;283:33394-33405.
22. Yamakuchi M, Ferlito M, Lowenstein CJ: MiR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci U S A. 2008;105:13421-13426.
23. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM: MiR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005;102:13944-13949.
24. Crawford M, Brawner E, Batte K, Yu L, Hunter MG, Otterson GA, Nuovo G, Marsh CB, Nana-Sinkam SP: MicroRNA- 126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem Biophys Res Commun. 2008;373:607-612.
25. Zhu S, Wu H, Wu F, Nie D, Sheng S, Mo YY: MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res. 2008;18:350-359.
26. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, Jackson AL, Linsley PS, Chen C, Lowe SW, Cleary MA, Hannon GJ: A microRNA component of the p53 tumour suppressor network. Nature. 2007;447:1130-1134.
27. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, Zhai Y, Giordano TJ, Qin ZS, Moore BB, Mac- Dougald OA, Cho KR, Fearon ER: P53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol. 2007;17:1298-1307.
28. Raver-ShapiraN,Marciano E, Meiri E, Spector Y, RosenfeldN, Moskovits N, Bentwich Z, Oren M: Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell. 2007;26:731-743.
29. Yan HL, Xue G, Mei Q,Wang YZ, Ding FX, LiuMF, Lu MH, Tang Y, Yu HY, Sun SH: Repression of the miR-17-92 cluster by p53 has an important function in hypoxia-induced apoptosis. EMBO J. 2009;28:2719-2732.
30. Song B, Wang Y, Kudo K, Gavin EJ, Xi Y, Ju J: MiR- 192 Regulates dihydrofolate reductase and cellular proliferation through the p53-microRNA circuit. Clin Cancer Res. 2008;14:8080-8086.
31. Braun CJ, Zhang X, Savelyeva I, Wolff S, Moll UM, Schepeler T, Ørntoft TF, Andersen CL, Dobbelstein M: P53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res. 2008;68:10094-100104.
32. Park SY, Lee JH, Ha M, Nam JW, Kim VN: MiR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat StructMol Biol. 2009;16:23-29.
33. Fornari F, Gramantieri L, Giovannini C, Veronese A, Ferracin M, Sabbioni S, Calin GA, Grazi GL, Croce CM, Tavolari S, Chieco P, Negrini M, Bolondi L: MiR- 122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 2009;69:5761-5767.
34. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM, Harris CC: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9:189-198.
35. Cowden Dahl KD, Dahl R, Kruichak JN, Hudson LG: The epidermal growth factor receptor responsive miR-125a represses mesenchymal morphology in ovarian cancer cells. Neoplasia. 2009;11:1208-1215.
36. Herrera BM, Lockstone HE, Taylor JM, Wills QF, Kaisaki PJ, Barrett A, Camps C, Fernandez C, Ragoussis J, Gauguier D, McCarthy MI, Lindgren CM: MicroRNA-125a is overexpressed in insulin target tissues in a spontaneous rat model of type 2 diabetes. BMC Med Genomics. 2009;2:54.
37. Li W, Duan R, Kooy F, Sherman SL, Zhou W, Jin P: Germline mutation of microRNA-125a is associated with breast cancer. J Med Genet. 2009;46:358-360.
38. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, SchulerM, Green DR: Direct activation of Bax by p53mediates mitochondrialmembrane permeabilization and apoptosis. Science. 2004;13;30:1010-1014.
39. Wolkowicz R, Elkind NB, Ronen D, Rotter V: The DNA binding activity of wild type p53 is modulated by blocking its various antigenic epitopes. Oncogene. 1995;10:1167-1174.
40. Hupp TR,Meek DW,Midgley CA, Lane DP: Regulation of the specific DNA binding function of p53. Cell. 1992;71:875-886.
41. Wade-Evans A, Jenkins JR: Precise epitope mapping of the murine transformation-associated protein, p53. EMBO J. 1985;4:699-706.
42. Mercer WE, Shields MT, Lin D, Appella E, Ullrich SJ: Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression. Proc Natl Acad Sci U S A. 1991;88:1958-1962.
43. Janus F, Albrechtsen N, Knippschild U, Wiesmüller L, Grosse F, Deppert W: Different regulation of the p53 core domain activities 3'-to-5' exonuclease and sequence-specific DNA binding. Mol Cell Biol. 1999;19:2155-2168.
44. Gwinn MR, Leonard SS, Sargent LM, Lowry DT, McKinstry K, Meighan T, Reynolds SH, Kashon M, Castranova V, Vallyathan V: The role of p53 in silica-induced cellular and molecular responses associated with carcinogenesis. J Toxicol Environ Health A. 2009;72:1509-1519.
45. Zhang B, Pan X, Cobb GP. Anderson TA: MicroRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302:1-12.
46. Inamura K, Togashi Y, Nomura K, Ninomiya H, Hiramatsu M, Satoh Y, Okumura S,NakagawaK, Ishikawa Y: Let-7 microRNA expression is reduced in bronchioloalveolar carcinoma, a noninvasive carcinoma, and is not correlated with prognosis. Lung Cancer. 2007;58:392-396.
47. Calin GA, Cimmino A, Fabbri M, Ferracin M, Wojcik SE, Shimizu M, Taccioli C, Zanesi N, Garzon R, Aqeilan RI, Alder H, Volinia S, Rassenti L, Liu X, Liu CG, Kipps TJ, Negrini M, Croce CM: MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A. 2008;105: 5166-5171.
48. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, Zeng YX, Shao JY: MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA. 2008;14:2348-2360.
49. Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Georgoulias V, Lianidou ES: Prognostic value of mature microRNA- 21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem. 2008;54:1696-1704.
50. Eis PS, Tam W, Sun L, Chadburn A, Li Z, Gomez MF, Lund E, Dahlberg JE: Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A. 2005;102:3627-3632.
51. Guo X, Wu Y, Hartley RS: MicroRNA-125a represses cell growth by targeting HuR in breast cancer. RNA Biol. 2009;6:575-583.
52. Tong X, Pelling JC: Enhancement of p53 expression in keratinocytes by the bioflavonoid apigenin is associated with RNAbinding protein HuR. Mol Carcinog. 2009;48:118-129.
53. Lee I, Ajay SS, Yook JI, Kim HS, Hong SH, Kim NH, Dhanasekaran SM, Chinnaiyan AM, Athey BD: New class of microRNA targets containing simultaneous 5'-UTR and 3'- UTR interaction sites. Genome Res. 2009;19:1175-1183.
54. Tay Y, Zhang J, Thomson AM, Lim B, Rigoutsos I: MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature. 2008;455:1124-1128.